The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders--a double-blind placebo-controlled study.
The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo-controlled study involving 40 patients. The intended study period was 18 months. The results showed zimeldine to be significantly more effective than placebo, both in terms of preventing recurrence (t-test: P less than 0.001) and the withdrawal rate (Cox's test: P less than 0.01). Adverse symptoms for zimeldine did not differ from placebo. There were no noteworthy changes in clinical chemistry, blood pressure, ECG and pulse rate.
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012008:Recurrence; D015031:Zimeldine / Q000009:adverse effects / Q000627:therapeutic use*
D015031:Zimeldine